phase I clinical study Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 17, 2023 Yantai LNC Biotechnology to Use Sofie Biosciences Imaging Agent to ID Patients for Theranostic Trial Jan 17, 2023 Leap Therapeutics Merges With Flame Biosciences to Advance Several Precision Oncology Drugs Jan 17, 2023 Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback Jan 11, 2023 Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial Jan 9, 2023 Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers Jan 6, 2023 Arsenal Biosciences Begins Phase I Trial of Cell Therapy in Ovarian Cancer Jan 5, 2023 Theseus Reveals Development Milestones for its Precision Oncology Programs in 2023 Jan 4, 2023 Orano Med Commences Phase I Trial of Lead Radiopharmaceutical in GRPR-Expressing Solid Tumors Jan 4, 2023 Nuvectis Partners With ENGOT, GOG Foundation on Phase Ib Ovarian Cancer Trial of HSF1 Inhibitor Dec 20, 2022 Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors Dec 15, 2022 Immix Biopharma Forms New Subsidiary, In-Licenses Multiple Myeloma CAR T-Cell Therapy Dec 14, 2022 Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 11, 2022 Menin Inhibitors Show Activity in AML With NPM1, KMT2A Alterations Premium Dec 8, 2022 KSQ Therapeutics Begins Combination Dosing in Trial of USP1 Inhibitor for Advanced Solid Tumors Dec 8, 2022 Mirati Therapeutics Sees First-Line Potential in Adagrasib-Keytruda Combo Premium Dec 2, 2022 Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy Dec 1, 2022 Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors Premium Nov 30, 2022 Erasca Inks Deal With Pierre Fabre on ERAS-007, Braftovi Combo Study in Colorectal Cancer Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
